🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕 A meta-analysis reveals intriguing sex-related differences in immunotherapy for hepatocellular carcinoma: ✳️ 5 Phase III trials included, females showed smaller overall survival ✅ No significant sex-based differences in safety profiles 🌏 While real-world data coming from an

❕A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 🔓#OpenAccess at 👉 jhep-reports.eu/article/S2589-… #LiverTwitter

Immunotherapy is truly changing all stages of hepatocellular carcinoma⁦. Honoured to have been tasked to make sense of this change with ⁦Antonio D'Alessio⁩ ⁦Claudia Angela M. Fulgenzi⁩ for ⁦Nature Medicine⁩ ⁦Surgery and Cancer⁩ ⁦UPO - Università⁩ nature.com/articles/s4159…

"Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease" now free to read at bit.ly/49T2dFj #livertwitter

🔥news from #EASL2024 Outcome of pts with HCC who achieved a complete response to ICI-based therapy 👉🗺️RWD, 174/3933 pts 👉mRFS 30 mo, 3yr OS 87% 😅Great to report recurrence free survival (!) after systemic therapy in advanced HCC ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Great study by Bernhard Scheiner on outcomes of patients with HCC who achieved complete response on immunotherapy-based regimens Improved outcomes among patients who continued therapy beyond 6 mos after CR, suggesting we should continue therapy if well-tolerated #EASLCongress

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction - another piece of the puzzle by Claudia Angela M. Fulgenzi Surgery and Cancer UPO - Università jamanetwork.com/journals/jamao…

Our paper on immunotherapy in CPB HCC is out on JAMA Oncology! Thanks to all the co-authors for their precious support! A special acknowledgment is for Alessio Cortellini for his invaluable statistical support, and to the rest of my amazing team David James Pinato 🇺🇦 Antonio D'Alessio Ciro Celsa

Very proud and thankful to see this study on metabolomic profiles in cirrhosis and PSVD finally published. I am more than grateful for the team working on this project - especially @GeorgSemmler and Oleksandr Petrenko | opetrenko.bsky.social as well as our collaboration partners JC Garcia Pagan! 😀

⁉️ What to do after response achievement with #immunotherapy in #HCC? 🧐 No definitive answer. Here we share some thoughts 💭 with Giuseppe Cabibbo 🐚 ⚠️ The study of Bernhard Scheiner out in HEPATOLOGY Journal soon!

#LiverX Metabolomic profiles differentiate between porto-sinusoidal vascular disorder (#PSVD) & cirrhosis (#ACLD) 🟢 taurocholic acid (AUROC 0.899) 📕JHEP Reports by @GeorgSemmler Oleksandr Petrenko | opetrenko.bsky.social Bernhard Scheiner JC Garcia Pagan 🔗sciencedirect.com/science/articl…

Outcome of pts with HCC who achieved CR to ICI-based systemic therapy HEPATOLOGY Journal doi.org/10.1097/HEP.00… 🔎🌎RWD, 3933 pts 👉1- & 3-year RFS: 78% & 55% 👉1- & 3-year OS: 98% & 86% 😅Just great to report RFS in advanced HCC w/ ICI❗️ 🧐only 4%, but we are getting there... ESMO - Eur. Oncology

Join us at the EASL #LiverCancerSummit 2025, on 20-22 February in Paris & online! 🌍 🦀Dive into cutting-edge research, expert-led sessions, and networking with global specialists in liver cancer care. Don’t miss this chance to explore breakthroughs in hepatocellular and

🔥New research--> focusing on longitudinal body composition trajectories in #HCC patients Falling trajectories with refractory #cachexia/#sarcopenia are linked to 👉 poorest survival rates 👉poorest response to #immunotherapies. Special thanks to David James Pinato 🇺🇦 Bernhard Scheiner

#twitterliver #PortalHypertension WP1 focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with compensated advanced chronic liver disease & investigates potentially beneficial effects of telmisartan in this patient group.⬇️⬇️

#xliver #PortalHypertension #ClinicalTrials FANs! 👋 Introducing the next work-package focusing on patients with porto-sinusoidal vascular disorder. #PSVD 🌐More info in the video below 🔽